WO2002054065A2 - Reversible mhc multimer staining for functional purification of antigen-specific t cells - Google Patents
Reversible mhc multimer staining for functional purification of antigen-specific t cells Download PDFInfo
- Publication number
- WO2002054065A2 WO2002054065A2 PCT/EP2001/015353 EP0115353W WO02054065A2 WO 2002054065 A2 WO2002054065 A2 WO 2002054065A2 EP 0115353 W EP0115353 W EP 0115353W WO 02054065 A2 WO02054065 A2 WO 02054065A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- binding
- cell
- partner
- cells
- mhc
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 190
- 238000010186 staining Methods 0.000 title claims abstract description 87
- 230000002441 reversible effect Effects 0.000 title claims abstract description 61
- 239000000427 antigen Substances 0.000 title claims abstract description 36
- 108091007433 antigens Proteins 0.000 title claims abstract description 36
- 102000036639 antigens Human genes 0.000 title claims abstract description 36
- 238000000746 purification Methods 0.000 title claims abstract description 28
- 210000004027 cell Anatomy 0.000 claims abstract description 156
- 238000000034 method Methods 0.000 claims abstract description 66
- 238000002955 isolation Methods 0.000 claims abstract description 17
- 230000027455 binding Effects 0.000 claims description 168
- 239000003153 chemical reaction reagent Substances 0.000 claims description 80
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 79
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 68
- 108020003175 receptors Proteins 0.000 claims description 47
- 102000005962 receptors Human genes 0.000 claims description 47
- 108010090804 Streptavidin Proteins 0.000 claims description 40
- 239000003446 ligand Substances 0.000 claims description 40
- 108091008874 T cell receptors Proteins 0.000 claims description 32
- 238000012546 transfer Methods 0.000 claims description 31
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 28
- 229960002685 biotin Drugs 0.000 claims description 28
- 235000020958 biotin Nutrition 0.000 claims description 28
- 239000011616 biotin Substances 0.000 claims description 28
- 108090001008 Avidin Proteins 0.000 claims description 25
- 238000010494 dissociation reaction Methods 0.000 claims description 21
- 230000005593 dissociations Effects 0.000 claims description 21
- 238000000338 in vitro Methods 0.000 claims description 21
- 230000003993 interaction Effects 0.000 claims description 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 15
- 230000004927 fusion Effects 0.000 claims description 12
- 229920001184 polypeptide Polymers 0.000 claims description 10
- 150000001615 biotins Chemical class 0.000 claims description 8
- 108010018381 streptavidin-binding peptide Proteins 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 5
- 230000001627 detrimental effect Effects 0.000 claims description 3
- 238000009169 immunotherapy Methods 0.000 claims description 3
- 108010028230 Trp-Ser- His-Pro-Gln-Phe-Glu-Lys Proteins 0.000 claims description 2
- 150000001768 cations Chemical class 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 238000011160 research Methods 0.000 abstract description 7
- 238000012512 characterization method Methods 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 4
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 121
- 238000001727 in vivo Methods 0.000 description 20
- 229940068840 d-biotin Drugs 0.000 description 18
- 230000003915 cell function Effects 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 11
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 11
- 229920000642 polymer Polymers 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 239000003550 marker Substances 0.000 description 10
- 230000009089 cytolysis Effects 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 7
- 229930040373 Paraformaldehyde Natural products 0.000 description 6
- 229920002866 paraformaldehyde Polymers 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000007781 signaling event Effects 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 102000000584 Calmodulin Human genes 0.000 description 4
- 108010041952 Calmodulin Proteins 0.000 description 4
- 241000186779 Listeria monocytogenes Species 0.000 description 4
- -1 aliphatic amino acid Chemical class 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000002825 functional assay Methods 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000003226 mitogen Substances 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 230000004962 physiological condition Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 3
- 108090000672 Annexin A5 Proteins 0.000 description 3
- 102000004121 Annexin A5 Human genes 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 229930003756 Vitamin B7 Natural products 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000981 bystander Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 238000010230 functional analysis Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000010187 selection method Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000009258 tissue cross reactivity Effects 0.000 description 3
- 235000011912 vitamin B7 Nutrition 0.000 description 3
- 239000011735 vitamin B7 Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000011510 Elispot assay Methods 0.000 description 2
- 206010024641 Listeriosis Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000006287 biotinylation Effects 0.000 description 2
- 238000007413 biotinylation Methods 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 230000009920 chelation Effects 0.000 description 2
- 230000009137 competitive binding Effects 0.000 description 2
- 230000001461 cytolytic effect Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000002297 mitogenic effect Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000011476 stem cell transplantation Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- LZOIGVDSAMDBIO-LXWJMTKESA-N (2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-4-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](N)CCSC)C1=CC=CC=C1 LZOIGVDSAMDBIO-LXWJMTKESA-N 0.000 description 1
- AUTOLBMXDDTRRT-JGVFFNPUSA-N (4R,5S)-dethiobiotin Chemical compound C[C@@H]1NC(=O)N[C@@H]1CCCCCC(O)=O AUTOLBMXDDTRRT-JGVFFNPUSA-N 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- DEQPBRIACBATHE-FXQIFTODSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-2-iminopentanoic acid Chemical compound N1C(=O)N[C@@H]2[C@H](CCCC(=N)C(=O)O)SC[C@@H]21 DEQPBRIACBATHE-FXQIFTODSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 101100260565 Dictyostelium discoideum thyA gene Proteins 0.000 description 1
- 108010020195 FLAG peptide Proteins 0.000 description 1
- XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 108010066345 MHC binding peptide Proteins 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102400000745 Potential peptide Human genes 0.000 description 1
- 101800001357 Potential peptide Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 108010013985 adhesion receptor Proteins 0.000 description 1
- 102000019997 adhesion receptor Human genes 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003622 anti-hsv Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- LWISPDYGRSGXME-YDHLFZDLSA-N biotin peg2 amine Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCOCCOCCN)SC[C@@H]21 LWISPDYGRSGXME-YDHLFZDLSA-N 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000010370 cell cloning Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000009146 cooperative binding Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000010820 immunofluorescence microscopy Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 108010023260 immunoglobulin Fv Proteins 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 101150068774 thyX gene Proteins 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4648—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
Definitions
- the present invention relates to a new method for reversible staining and functional isolation or characterization of cells, particularly of antigen- specific T cells. With this technique, the original functional status of T cells o can be substantially maintained after their identification and purification. Thus, this new method is of broad benefit for basic research and clinical applications.
- Yee et al. J. Immunol. 162 (1999), 2227-2234) describe the isolation of high avidity melanoma-reactive cytotoxic T lymphocytes (CTL) from heterogeneous populations using peptide-MHC tetramers.
- the MHC tetramers are biotinylated and irreversibly conjugated to avidin containing o a fluorescent labeling group. A removal of the fluorescent marker under physiological conditions is thus not possible.
- Youde et al. (Cancer Res. 60 (2000), 365-371 ) describe the use of fluorescence labelled MHC tetramers to isolate human CTLs recognizing endogeneous human papilloma virus antigens.
- biotinylated MHC molecules are used, which are irreversibly bound to streptavidin under physiological conditions so that a removal of the detection reagent from the T cells is not possible.
- US-A-5,985,658 describes a method for separating target cells from a plurality of cells which is based on a reversible high affinity interaction.
- the method comprises forming a target cell/cell binding reagent/first molecule/second molecule/solid support complex, wherein the cell binding reagent is specific for target cells, e.g. an antibody, wherein the first molecule reversibly binds to the second molecule, wherein one of the first and second molecules is calmodulin, and wherein the other of the first and second molecules is a calmodulin-binding peptide.
- the binding between first and second molecule is reversed, thereby releasing target cells as separate cells from the plurality of starting cells.
- the disadvantage of this method is that the target cell binding agent must have a high affinity for the target cell, in order to enable an isolation of the target cell population. Thus, after removal of the binding between first and second molecule the target cell-specific reagent remains bound to the target cell.
- Endothelial cells are labelled by specific antibodies and then purified via binding to microbeads. Also this method includes the above mentioned disadvantages.
- T cells recognize processed antigen-fragments (epitopes) in the context of major histocompatibility complexes (MHC) (6).
- MHC major histocompatibility complexes
- TCR T cell receptor
- Multimerization of MHC/peptide increases the relative avidity of the interaction with TCRs to an extent which allows stable and epitope-specific binding on the T cell surface (Fig. 1 B).
- MHC multimer reagents conjugated with fluorochromes can be used for direct identification of antigen-specific T cells by flow cytometry. This method has revolutionized T cell research over the last few years, allowing to visualize antigen-specific T cell populations for the first time directly ex vivo, in animal models as well as in humans (7, 8). As long as MHC multimer staining is performed at 4°C, T cells can be identified and purified (FACS, MACS) without altering their original phenotype.
- MHC multimer reagents represent the natural ligand bound to the TCR
- placement of cells into in vitro cell culture or adoptive in vivo transfer into recipients results in dramatic alteration of purified T cell populations (Figs. 3 + 4), including TCR intemalization, activation, overstimulation, and cell death.
- a subject matter of the present invention is a method for reversible staining of cells comprising the steps:
- the first partner(s) and the further partner(s) of the binding complex are capable of forming a reversible bond and wherein an aggregate comprising at least two components (i), at least one component (ii) and at least one component (iii) is bound via the receptor molecule to said cell, wherein said cell is stained, (c) optionally separating said stained cell from other components of said sample and (d) optionally removing said staining from said cell by disrupting the reversible bond.
- TCR T cell receptor
- TCR binding ligand e.g. a TCR binding peptide and an MHC molecule conjugated to at least one first partner of a binding complex
- the first partner(s) and the further partner(s) of the binding complex are capable of forming a reversible bond and wherein an aggregate comprising at least two TCR binding ligands (i), at least one component (ii) and at least one component (iii) is bound via the TCR molecule to said T cell, wherein said T cell is stained,
- the method of the present invention is suitable for reversible staining of cells having a functional receptor molecule, e.g. of T cells, i.e. cells having a functional TCR molecule, wherein said receptor molecule is capable of binding to a receptor ligand, e.g. a peptide/MHC complex.
- the receptor ligand may be any molecule capable of binding to a receptor molecule present on the cell to be stained, particularly when the receptor ligand and the receptor molecule exhibit a low affinity interaction, e.g.
- a single molecule of the receptor ligand is not capable of forming a stable bond with the receptor on the target cell.
- at least two or more ligand molecules have to bind cooperatively to the receptor molecules on the target cell. This cooperative binding is accomplished by using ligand molecules conjugated to a first partner of a binding pair which is coupled to the further partner of the binding pair which has two or more, e.g. 3, 4, 5 or more, binding sites for first partner-ligand conjugates. If a single ligand molecule has a very low binding affinity, the number of cooperatively bound ligand molecules has to be increased in order to provide sufficient avidity for the formation of a stable bond.
- a ligand molecule may be conjugated to one or more first partners of a binding pair.
- a first partner e.g. a peptide
- the ligand molecule comprises at least two first binding partners, for example, a first binding partner may be coupled to the a chain of the MHC molecule and another first binding partner may be coupled to the ⁇ chain of the MHC molecule.
- first binding partner molecules may be conjugated to a ligand molecule or a subunit of the ligand molecule such as the a and/or ⁇ chain of an MHC molecule.
- suitable receptor molecules having low affinity interactions towards their ligands are cell adhesion receptor molecules such as described in (14) and receptors for costimulatory molecules such as described in (15).
- cell adhesion receptor molecules such as described in (14)
- receptors for costimulatory molecules such as described in (15).
- Still further examples are low affinity antibodies and fragments thereof and artificially engineered binding molecules such as peptides, lipochalins and other aptamers, e.g. from random libraries which bind molecules located on the cell surface and which exhibit low binding affinity but specific binding characteristics.
- the receptor ligand comprises an MHC specific peptide
- the peptide is a T cell epitope capable of binding to the TCR receptor of the cell to be analysed and to the MHC molecule.
- the cell is preferably a mammalian cell, e.g. a mammalian T cell, particularly a human cell, e.g. a human T cell, particularly a subpopulation of mammalian T cells having a predetermined antigen- specifity.
- the peptide comprises a T cell epitope capable of binding to a TCR molecule, preferably to a TCR molecule having a predetermined antigen- specifity.
- the peptide usually has a length of about 8 to about 25 amino acids and preferably comprises so-called anchor amino acid residues capable of allele-specific binding to a predetermined MHC molecule class, e.g. an MHC class I, an MHC class II or a non-classical MHC class.
- the MHC molecule is preferably a recombinant soluble MHC molecule, which may be prepared in a bacterial expression system (16) or in an insect cell expression system (17).
- a binding complex e.g. a binding pair is selected consisting of at least one first partner and at least one further partner wherein the at least further partner has at least two binding sites and more preferably at least four binding sites for the first partner.
- the bond between the first and the second partner should be reversible, i.e. the bond should be capable of being disrupted under conditions suitable for carrying out the claimed method.
- the reversible bond has a K d between 10 "2 and 10 "13 M, more preferably between 10 '3 and 10 '10 M and most preferably between 10 "5 and 10 '8 M as determined under appropriate conditions, e.g. by fluorescence titration (1 1 ).
- Particularly preferred is a reversible bond having a high K off value, e.g. 5 between 10 '1 sec "1 and 10 '4 sec "1 , especially between 10 '2 sec "1 and 10' 3 sec "1 .
- the staining of the target cell e.g. the T cell
- the subsequent optional steps namely o the isolation and purification of the stained target cell, e.g. the T cell
- the removal of the staining may be carried out at low temperatures, i.e. at temperatures where substantially no activation and/or signalling events occur, which might result in an alteration of the target cell, e.g. the T cell phenotype.
- the staining and the subsequent removal of the 5 staining is carried out at a temperature of ⁇ 15°C, more preferably ⁇ 10°C and most preferably at about 4°C.
- the separation of the stained target cell, e.g. the T cell, from other sample components, e.g. unstained T cells may be effected by conventional o methods, e.g. cell sorting, preferably by FACS methods using commercially available systems (e.g. FACSVantage by Becton Dickinson or Moflo by Cytomation), or by magnetic cell separation (e.g. MACS by Miltenyi).
- conventional o methods e.g. cell sorting, preferably by FACS methods using commercially available systems (e.g. FACSVantage by Becton Dickinson or Moflo by Cytomation), or by magnetic cell separation (e.g. MACS by Miltenyi).
- the removal of the staining preferably occurs by targeted disruption of the 5 reversible bond between the first and the second partner of the binding complex.
- This disruption may be achieved by contacting the stained cell with a free first partner of the binding complex or an analog thereof capable of disrupting the bond between the conjugated first partner (i) and the further partner (ii).
- the free first partner is an analog of the o conjugated first partner having a higher affinity to the further partner than the conjugated first partner.
- the free first partner has an affinity which is at least 3 orders of magnitude and particularly at least 5 orders of magnitude higher than the affinity of the conjugated first partner.
- the free first partner has a dissociation constant K d which is at least by a factor of 1 x1 0 "3 and especially 1 x10 '5 lower.
- the label which is used for the detection of stained cells may be any label which is used in diagnostic and analytical methods. Preferably the label does not negatively affect the characteristics of the cells in the method as described. Preferred examples of labels are fluorescent dyes or magnetic labels.
- the label may be bound to the ligand, e.g. the peptide and/or the MHC molecule, the first partner and/or the further partner of the binding complex.
- the label may be a direct label, i.e. a label bound to one of the members of the aggregate as specified above.
- the label may be an indirect label, i.e. a label which is bound to a receptor which in turn is capable of binding to one of the members of the aggregate as specified above.
- the removal of the staining from the target cell by disruption of the reversible bond between the first and the second partner results in a loss of the cooperative bond between at least two low-affinity ligands and receptor molecules on the target cell.
- the aggregate comprising at least two components (i), at least one component (ii) and at least one component (iii) is completeley disrupted. This results in a complete removal of any reagent bound to the target cell, because the bond between the receptor-binding component and the receptor on the target cell is a low- affinity interaction.
- the binding complex is selected from: (a) (i) biotin and (ii) a streptavidin or avidin analog capable of reversible binding of biotin, (b) (i) a biotin analog capable of reversible binding to streptavidin or avidin and (ii) streptavidin or avidin or a streptavidin or avidin analog capable of reversible binding of said biotin analog, and
- oligomers or polymers of streptavidin or of avidin or of analogs of streptavidin or of avidin may be prepared by the introduction of carboxyl residues into a polysaccharide, e.g. dextran essentially as described in "Noguchi, A., Takahashi, T., Yamaguchi, T., Kitamura, K., Takakura, Y., Hashida, M. & Sezaki, H. (1 992) .
- the streptavidin binding peptide is preferably selected from the Strep-tag peptides as described in (9), (10) or in U.S. patent 5,506, 1 21 which are herein incorporated by reference. More preferably, the Strep-tag peptides comprise the amino acid sequence Trp-X-His-Pro-Gln-Phe-Y-Z, wherein X is any desired amino acid and Y and Z either both are Gly, or Y is Glu and Z is Arg or Lys. Especially preferred is the peptide Trp-Ser-His-Pro-Gln-Phe- Glu-Lys (Strep-tagll).
- the binding complex may be selected from calmodulin-binding peptides and calmodulin as described in US-A- 5,985,658 or from any other interactions based on the presence of a divalent cation, particularly from peptides binding to a receptor, e.g. the FLAG peptide, which binds to the monoclonal antibody 4E1 1 as described in US-A-4,851 ,341 .
- the disruption of these binding complexes may be accomplished by metal ion chelation, e.g. calcium chelation, e.g. by addition of EDTA.
- MHC multimers increase the "relative binding avidity" but not the affinity of monovalent TCR-MHC/peptide interactions (Fig. 1 A). Since monomeric MHC/peptide complexes do not stably bind to TCRs, a targeted disruption of MHC multimers into MHC monomers results in rapid dissociation of surface bound TCR ligands. After complete dissociation of MHC/peptide complexes (at temperatures where no activation/signaling events occur, preferable at 4°C), the functional status of the T cell is not changed upon subsequent transfer to cell culture or adoptive in vivo transfer.
- the method of the present invention is a technique allowing fast and targeted disruption of MHC multimer reagents under physiological conditions for functional isolation of antigen-specific T cells; particularly a substantially complete and fast disruption at low temperatures [preferably at 4°C]. Further, the procedure is substantially non-toxic to T cells, and the substances used are harmless for (clinical) in vivo applications.
- the streptavidin muteins are characterized in that at position 44 of wild-type streptavidin Glu is replaced by a hydrophobic aliphatic amino acid e.g. Val, Ala, lie or Leu, at position 45 an arbitrary amino acid is present, at position 46 an aliphatic amino acid and preferably a hydrophobic aliphatic amino acid is present and/or at position 47 Val is replaced by a basic amino acid e.g. Arg or Lys and in particular Arg. More preferably, Ala is at position 46 and/or Arg is at position 47 and/or Val or lie is at position 44.
- a hydrophobic aliphatic amino acid e.g. Val, Ala, lie or Leu
- the mutein has a sequence selected from lle 44 -Gly 45 -Ala 6 -Arg 47 or Val 44 -Thr 45 -Ala 46 -Arg 47 ("Sfrep-Tactin" as described in (1 1 )) .
- the interaction of the Strep-tagll peptide with Strep- Tactin is characterized by a binding affinity with a K d of approx. 10 '6 M (1 1 ) compared to approx. 10 "13 M for the biotin-streptavidin interaction.
- Biotin which still binds with high affinity to Sfrep-Tactin (with a K d estimated to be between 10 '10 M and 10 '13 M), competes with Sfrep-tagll for the binding site.
- stable MHC multimers for antigen- specific T cell staining are generated based on the interaction of Strep- tagll/SfrepTactin.
- This system fulfills the required criteria for disruption of MHC multimers (see also above): because of the extreme affinity differences between Sfrep-tagll/SfrepTactin and biotin/SfrepTactin, complete and very fast competitive binding of biotin (even at low temperatures) takes place; biotin (tested up to a concentration of 50 mM) is non-toxic for T cells and does not alter T cell function and small amounts of biotin (vitamin H) are harmless for in vivo applications.
- streptavidin-binding peptides known in the art may be used, e.g. as described by Wilson et al. (Proc.Natl.Acad.Sci.USA 98 (2001 ), 3750-3755).
- binding complexes between streptavidin or avidin or analogs thereof and biotin or biotin analogs or streptavidin- or avidin-binding peptides are suitable for the purpose of the invention, provided they allow reversible staining of a cell which can be disrupted by the addition of compounds such as biotin or biotin analogs which do not show any detrimental effect to the cell to be stained.
- an antigen/antibody-binding pair can be applied, particularly if a polymerized or oligomerized antibody is used.
- binding complexes besides streptavidin/avidin and their analogs and/or antibodies may be so called engineered protein scaffolds for molecular recognition as published in "Skerra A. (2000). Engineered protein scaffolds for molecular recognition. J. Mol. Recognit. 13, 167-187” after being engineered to recognize compounds which may be disrupted in a targeted manner by disruption using biotin or biotin analogs.
- the present invention relates to a substantially pure target cell population which is defined by the presence of a specific common receptor and which has been purified from a heterogeneous cell population (i.e. heterogeneous relating to the presence or absence of the specific common receptor) using an affinity reagent binding to said common receptor.
- the target cell population is characterized in that the affinity reagent has been substantially completely removed (preferably below the detection limit) from said receptor. The complete removal of the affinity reagent is accomplished by using the reversibly multimerized low affinity ligand as described above.
- a target cell population is provided having a functional status (defined by the common specific receptor) which has not been altered by the purification method.
- the common specific receptor which defines the target cell population may be any receptor against which a low affinity ligand as described above may be directed.
- the receptor may be an antigen defining a cell population or subpopulation, e.g. a population or subpopulation of blood cells, e.g. lymphocytes, monocytes or natural killer cells, bone marrow cells or stem cells, e.g. CD34-positive peripheral stem cells.
- the receptor may also be a marker for tumor cells.
- the present invention relates to a substantially pure antigen- specific T cell population having a functional status which is substantially unaltered by a purification procedure comprising staining the desired T cell population, isolating the stained T cell population from a sample comprising o non-stained T cell population and removing said stain, i.e. the functional status of the T cell population before purification is substantially the same as after the purification.
- This T cell population may be obtained by the method as described above. More particularly, a T cell population is provided which is substantially free from any binding reagents used for the 5 isolation of the population, e.g. antibodies or TCR binding ligands such as multimeric TCR binding ligands.
- the present invention relates to a fusion polypeptide comprising (a) at least one peptide domain which is a first partner of a binding complex o which is capable of forming a reversible bond with at least one further partner of the binding complex and (b) a ligand domain which binds specifically but with low affinity to a receptor on a cell surface.
- the fusion polypeptide is preferably a genetic fusion, wherein one or several sequentially clustered peptide domains are located on the N- and/or C- 5 terminus of the ligand domain.
- the fusion polypeptide may also consist of several subunits, wherein each subunit forms a ligand subdomain which bind together to the receptor.
- each subunit preferably contains at least one peptide domain.
- the fusion polypeptide comprises (a) a streptavidin-binding peptide and (b) an MHC o molecule, preferably a soluble MHC molecule.
- the streptavin- binding peptide may be fused to the N-terminus and/or the C-terminus of the ⁇ -chain and/or the ⁇ -microglobulin chain of an MHC molecule.
- fusion polypeptides comprising at least two streptavidin-binding peptides, e.g.
- fusion polypeptides having a streptavidin-binding peptide bound both to the C-terminus of the ⁇ -chain and the ⁇ -chain have been shown to be suitable for the purpose of the present invention.
- Preferred streptavin-binding peptides are Strep-tag peptides as described above, particularly Sfrep-tagll.
- the invention relates to nucleic acids encoding a fusion polypeptide as described above, wherein the nucleic acids are preferably located on a recombinant vector, particularly an expression vector allowing expression of the claimed fusion polypeptide in a suitable host cell, e.g. a eukaryotic or prokaryotic host cell.
- the method of the present invention allows a functional isolation of target cell populations, e.g. of antigen specific T cell populations based on a reversible staining procedure.
- the original functional status of target cells, e.g. T cells, can be substantially maintained after the identification and purification.
- the method of the invention is of broad benefit for basic research and clinical applications. Examples of preferred applications are as follows:
- T cell populations obtained ex vivo often requires further in vitro expansion to T cell lines or T cell clones.
- MHC multimer techniques single cells or distinct phenotypic subpopulations within a diverse T cell population can be isolated, but the binding of the reagents to the TCR interferes with the efficiency of in vitro expansion.
- This experimental problem is solved by reversible T cell staining using the reagents of the invention, e.g. MHC-Sfrep-tagll/Strep-Tactin reagents.
- MHC/peptide dissociation rates correlate with relative binding affinities ( 1 2, 1 3) .
- MHC-Sfrep-tagll/Sfrep-Tactin reagents MHC/peptide complexes can be accumulated on the cell surface of epitope- specific T cells and MHC dissociation rates can be determined after fast monomerization by addition of biotin. This is possible because removal of the Sfrep-Tactin backbone is significantly faster than MHC dissociation rates.
- antigen-specific T cell populations can be isolated directly ex vivo and expanded in vitro after dissociation of the reagents. This approach is expected to be much more efficient than purification using conventional MHC multimer reagents, as the binding of the reagents negatively interferes with the efficiency of in vitro T cell expansion.
- T cell populations from in vitro expanded cell lines or clones for further functional analyses or therapy.
- In vitro expansion of T cells requires the addition of antigen-presenting cells or feeder cells to the culture.
- antigen-presenting cells or feeder cells For further functional analysis, and especially for therapeutic applications (e.g. adoptive transfer), it would be helpful to remove these contaminating cells.
- the selection marker For positive selection procedures (which usually result in the highest degrees of purity), the selection marker should be removable from the T cell surface, as it might interfere with functional assays or adoptive transfer. If T cells are used for in vivo applications the selection marker must be further removed if it contains substances that could cause clinical complications such as allergic reactions.
- Reversible T cell staining e.g. using MHC-Sfrep-tagll/Sfrep-Tactin reagents fulfills all these criteria.
- An example for an important clinical application for this procedure is the parallel purification and adoptive transfer of EBV- and/or CMV-specific T cell populations during [otherwise] T cell-depleted stem cell transplantations, a protocol which is likely to dramatically reduce the incidence of EBV and CMV-related malignancies in transplant patients.
- Reversible T cell staining and isolation e.g. using MHC-Sfvep-tagll/Sfrep- Tactin reagents could be an ideal method for these clinical applications.
- MHC multimer techniques allow quantification and phenotypic characterization of antigen-specific T cells directly ex vivo.
- binding of multimer reagents to the TCR complicates the use of purified cells in functional assays (e.g. chronic virus infections [HIV, CMV, EBV, HBV, HCV], tumor-specific T cell populations).
- Reversible T cell staining and isolation e.g. using MHC-Sfrep-tagll/Sfrep- Tactin reagents opens the door for powerful evaluation of antigen-specific T cell status in many clinical situations.
- Fig. 1 The binding of monomeric and multimeric peptide/MHC conjugates to the TCR of T cells. Due to the binding of the peptide/MHC complex to the TCR, the functional status of the T cells is dramatically altered under physiological conditions (prior art).
- Fig. 2 By targeted disruption of peptide/MHC multimer binding to the TCR molecules the staining is removed resulting in a purified T cell population having substantially unaltered characteristics (invention).
- Fig. 3 Interference of MHC multimer staining with T cell function in vitro.
- LLO 91 . 99 -specific T cells were stained for 2 hours with binding (LLO 91 . 99 /H2-K d ) or non-binding (p60 217 . 225 /H2-K d ) streptavidin-PE tetramer ("tet") reagents at 4°C or 37°C.
- tet streptavidin-PE tetramer staining
- TCR expression middle, filled black graph hidden behind TCR h ⁇ gh populations
- annexin V binding lower
- Immunofluorescence staining of LLO 91 Immunofluorescence staining of LLO 91 .
- LLO 91 . 99 -specific T cells one hour after incubation with LLO 91 . 99 /H2-K d streptavidin-Alexa 546 tetramers (red) at 4°C or 37°C.
- LLO 91 . 99 peptide concentration and percent specific lysis are shown on the x- and y-axes, respectively. The bars indicate lysis of MHC mismatched target cells (10 '8 M LLO 91 .
- Fig. 4 Interference of MHC multimer staining with T cell function in vivo.
- LLO 91 . 99 -specific T cells were stained for 30 min with binding (LLO 91.99 /H2- K d ) or non binding (p60 217 . 225 /H2-K d ) tetramer ("tet") reagents, extensively washed to remove unbound reagent, and transferred into naive recipient mice. Six hours later, mice were infected with 2 x 10 4 Listeria monocytogenes. Numbered viable bacteria (y-axis) determined in the spleen 48 h post-infection are shown following adoptive transfer of 1 x 10 7 LLO 91.
- 99 -specific T cells (a) or various numbers of LLO 91 . 99 -specific T cells (b) treated with binding (LLO 91 . 99 /H2-K d , open bar) or non-binding (p60 217. 225 /H2-K d , filled bar) tetramer reagents (2 mice per group, standard deviations indicated). Control mice received NaCI only, (c) LLO 91 .
- poly 99 /K d streptagll/ ⁇ 2 -HSV-tag SfrepTactin polymers
- Fig. 6 Improvement of MHCstreptagll/SfrepTactin multimer reagents,
- (b) LLO 91 . 99 -specific T cells were stained for 45 min with LLO 91 _ 99 /K d streptagll/ ⁇ 2 -streptagll-HSV- tag SfrepTactin polymers ("poly”), briefly washed to remove unbound reagents, and incubated in the presence (upper histogram) or absence (lower histogram) of 1 mM biotin.
- Fig. 7 Reversible MHC multimer staining and T cell function.
- LLO 91 . 99 - specific T cells were stained for 30 min with binding LLO 91 . 99 /K d streptagll/ ⁇ 2 m-streptagll-HSV-tag StrepTactin or non-binding (p60 217 .
- 225 'H2-K d multimer reagents and then extensively washed over 4 h in the presence or absence or d-biotin (1 mM, all done at 4°C) prior to assays or adoptive transfer, (a) Staining for recombinant MHC-molecules (detected by epitope-tag staining, x-axis) on differently treated T cells, (b) Cytotoxicity (% specific lysis, y-axis) of differently treated T cells in response to LLO 91 . 99 peptide-coated target cells (peptide titration, x-axis) with an effector to target cell ratio of approx. 5:1 , compare with Fig. 1 c.
- mice Two groups of mice were injected with cells previously incubated with binding MHCstreptagll reagents (striped bars) and either washed (upper bar, large stripes) or not washed (lower bar, small stripes) in the presence of d-biotin.
- Control mice received cells treated with binding (open bar) or non-binding (filled bar) conventional MHC tetramer reagents (plus d-biotin wash) or were injected with NaCI only (grey bar). Numbers of viable bacteria (y-axis) were determined 48 h following Lysteria infection. Data are representative of three independent experiments, each with 2 mice per group.
- Fig. 8 Reversible MHC multimer staining can be transferred to human T cells.
- HLA*A0201 streptagll fusion proteins were generated and folded in the presence of recombinant human ⁇ 2 microglobulin-HSVtag-streptagll and the epitope MART1 27 . 35 to obtain soluble MHC molecules. These were 5 subsequently multimerized with streptactin-polymers and used for staining of a MART 27 . 35 -specific T cell clone (kindly provided by Burkhard Schmidt, Institute of Hematology, réelleumlogy der Isar, Kunststoff). MART1 27 .
- 35 - specific T cells were stained for 30 min at 4°C with HLA*A0201 streptagll- Streptactin multimer reagents; after washing, aliquots of the stained cells o were incubated for different periods of time in the presence of 1 mM d- biotin, all done at 4°C. Secondary staining for HSV-epitope was performed as described before (see also legend to Fig. 3); then cells were fixed in 1 % paraformaldehyde and analyzed by flow cytometry. Histograms show fluorescence intensity for HSV epitope tag staining. 5
- the pET3a/H2-Kd expression vector (5) was mutated by standard PCR techniques to exchange the C-terminal biotinylation site to the Sfrep-tagll sequence. Protein expression was induced in the expression host 5 BL2KDE3) by addition of IPTG and subsequently, inclusion bodies were purified as described before (5) .
- H2-Kd Strep-Tagil and mouse ⁇ 2 -microglobulin (containing a HSV epitope tag at the C-terminus) inclusion bodies were dissolved in 8 M urea and thereafter refolded by rapid dilution into arginine-rich buffer in the presence of high amounts of synthetic MHC binding peptide (here: 0.5 mg/ml LLO 91 . 99 , GYKDGNEYI or p60 217 . 225 , KYGVSVQDI, respectively) as described previously (5) .
- Soluble MHC complexes were further purified by gel filtration (Superdex 200HR, Pharmacia) and aliquots were stored in liquid nitrogen.
- MHC multimer reagents were stored at 2 mg/ml in PBS pH 8.0 containing 0.02% NaAzide, 0.1 mM EDTA, 1 ⁇ g/ml pepstatin, and 1 ⁇ g/ml leupeptin (5).
- H2-Kd Sfrep-tagll multimer reagent per 1 x 10 6 cells at 4°C for 30 min.
- epitope-tag staining cells were washed, fixed briefly in 1 % paraformaldehyde, and subsequently stained for anti-HSV tag using an unconjugated primary mouse or rat mAb (e.g. TB067, Novagen) and a secondary anti-mouse or anti-rat-PE antibody (e.g. A85-1 , PharMingen) .
- an unconjugated primary mouse or rat mAb e.g. TB067, Novagen
- a secondary anti-mouse or anti-rat-PE antibody e.g. A85-1 , PharMingen
- FCS usually at 4°C.
- Conventional 51 Cr-release and 3 H-thymidine incorporation assays were performed as described before (1 8). Adoptive transfer experiments
- CTLs cytotoxic T cells
- the degree of protection correlates with the number of transferred cells (Fig. 4b); while 1 x 10 7 CTLs pretreated with binding MHC tetramers still confer some significant ⁇ /sfer/a-specific protection Listeria infection in mice who received 1 x 10 6 cells is indistinguishable from untreated mice. Adoptive transfer of 1 x 10 s control CTLs still mediates significant protection. After cell transfer, much lower numbers of LLO 91 . g9 - specific T cells could be recovered from recipient mice who received MHC multimer-stained cells as compared to control cells (Fig. 4c); the same results were obtained tracking the transferred T cells with the allotypic surface marker thy1 .1 (data not shown). These data reveal a strong negative impact of MHC multimer staining on in vivo cell transfer, both in terms of survival and function.
- MHC multimers increase the "relative binding avidity" but not the affinity of TCR-MHC/peptide interactions.
- epitope-specific T cells demonstrate some detectable interaction with monomeric MHC/epitope molecules when fixed immediately with paraformaldehyde (Fig. 5a, upper histogram), after brief washing all reagent-derived MHC monomers disappear from the cell surface (Fig. 5a, lower histogram, performed at 4°C). Based on these observations, we postulated that targeted disruption of multimers into MHC monomers results in rapid dissocation of surface bound TCR ligand and - if all procedures performed at low temperatures - T cells might maintain the original functional status and phenotype (see model in Fig. 2).
- LLO 91 . 99 -specific T cell lines were stained with LLO 91 . 99 /K d (2x)streptagll StrepTactin-polymer reagents, and washed over 4 h in cold (4°C) buffer containing d-biotin (1 mM) or no d-biotin.
- cells were pretreated with binding (LLO 91 . 99 /H2-K d ) or non-binding (p60 217.227 /H2-K d ) conventional tetramer reagents.
- the MHC-streptagll multimer system fulfills all these requirements: ( 1 ) Because of the extreme affinity differences between streptagll/StrepTactin and d-biotin/StrepTactin, complete and very fast competitive binding is achieved even at low temperatures; (2) d-biotin (vitamin H) in low concentrations is non-toxic for T cells; we tested d-biotin up to a concentration of 50 mM and could not find evidence for toxicity or changes of T cell function; (3) the amounts of d-biotin that might be transferred together with reversibly stained T cells are far lower than d-biotin concentrations found in conventional vitamin supplementations and are therefore unlikely to be harmful.
- Purification of antigen-specific T cells also plays an important role in the improvement of T cell cloning strategies, especially when purified antigen-specific cells need to be further expanded by effective antigen-independent stimuli (mitogens or anti-CD3).
- mitogens or anti-CD3 effective antigen-independent stimuli
- the basis principle of the reversible multimer-staining procedure might be applicable to other low avidity receptor-ligand interactions.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Ecology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002554713A JP4416400B2 (en) | 2000-12-28 | 2001-12-28 | Reversible MHC multimer staining method for functional purification of antigen-specific T-cells |
US10/451,865 US7776562B2 (en) | 2000-12-28 | 2001-12-28 | Reversible MHC multimer staining for functional purification of antigen-specific T cells |
CA2467434A CA2467434C (en) | 2000-12-28 | 2001-12-28 | Reversible mhc multimer staining for functional purification of antigen-specific t cells |
EP01986941.1A EP1346217B1 (en) | 2000-12-28 | 2001-12-28 | Reversible mhc multimer staining for functional purification of antigen-specific t cells |
US12/843,763 US8298782B2 (en) | 2000-12-28 | 2010-07-26 | Reversible MHC multimer staining for functional purification of antigen-specific T cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00128634.3 | 2000-12-28 | ||
EP00128634A EP1227321A1 (en) | 2000-12-28 | 2000-12-28 | Reversible MHC multimer staining for functional purification of antigen-specific T cells |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10451865 A-371-Of-International | 2001-12-28 | ||
US12/843,763 Continuation US8298782B2 (en) | 2000-12-28 | 2010-07-26 | Reversible MHC multimer staining for functional purification of antigen-specific T cells |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002054065A2 true WO2002054065A2 (en) | 2002-07-11 |
WO2002054065A3 WO2002054065A3 (en) | 2002-11-28 |
Family
ID=8170850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2001/015353 WO2002054065A2 (en) | 2000-12-28 | 2001-12-28 | Reversible mhc multimer staining for functional purification of antigen-specific t cells |
Country Status (5)
Country | Link |
---|---|
US (2) | US7776562B2 (en) |
EP (2) | EP1227321A1 (en) |
JP (1) | JP4416400B2 (en) |
CA (1) | CA2467434C (en) |
WO (1) | WO2002054065A2 (en) |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1878744A1 (en) * | 2006-07-13 | 2008-01-16 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Epitope-tag for surface-expressed T-cell receptor proteins, uses thereof and method of selecting host cells expressing them |
EP2109669A2 (en) | 2006-11-15 | 2009-10-21 | Invitrogen Dynal AS | Methods for reversibly binding a biotin compound to a support |
CN102662054A (en) * | 2012-05-10 | 2012-09-12 | 东南大学 | Method for synchronously detecting quantity and functions of specific thymus dependent lymph cells |
WO2013011011A2 (en) | 2011-07-18 | 2013-01-24 | Iba Gmbh | Method of reversibly staining a target cell |
WO2013124474A2 (en) | 2012-02-23 | 2013-08-29 | Stage Cell Therapeutics Gmbh | Chromatographic isolation of cells and other complex biological materials |
WO2015158868A2 (en) | 2014-04-16 | 2015-10-22 | Juno Therapeutics Gmbh | Methods, kits and apparatus for expanding a population of cells |
WO2015166049A1 (en) | 2014-04-30 | 2015-11-05 | Iba Gmbh | Method of isolating a target cell |
EP3037821A1 (en) * | 2014-12-27 | 2016-06-29 | Miltenyi Biotec GmbH | Cell detection with conjugates having an enzymatically releasable detection moiety |
WO2016166568A1 (en) | 2015-04-16 | 2016-10-20 | Juno Therapeutics Gmbh | Methods, kits and apparatus for expanding a population of cells |
WO2017056362A1 (en) * | 2015-09-30 | 2017-04-06 | Sony Corporation | Method for analyzing cell, chip for cell analysis, reagent for cell analysis, kit for cell analysis, and apparatus for cell analysis |
WO2017068421A1 (en) | 2015-10-22 | 2017-04-27 | Juno Therapeutics Gmbh | Methods for culturing cells and kits and apparatus for same |
WO2017068419A2 (en) | 2015-10-22 | 2017-04-27 | Juno Therapeutics Gmbh | Methods, kits, agents and apparatuses for transduction |
WO2017068425A1 (en) | 2015-10-22 | 2017-04-27 | Juno Therapeutics Gmbh | Methods for culturing cells and kits and apparatus for same |
WO2018001985A1 (en) | 2016-06-28 | 2018-01-04 | Technische Universitaet Muenchen | Combination of reversible and irreversible cell labeling for analizing receptor-ligand koff rate |
US10030065B2 (en) | 2007-07-03 | 2018-07-24 | Dako Denmark A/S | MHC multimers, methods for their generation, labeling and use |
WO2018197949A1 (en) | 2017-04-27 | 2018-11-01 | Juno Therapeutics Gmbh | Oligomeric particle reagents and methods of use thereof |
US10336808B2 (en) | 2007-03-26 | 2019-07-02 | Dako Denmark A/S | MHC peptide complexes and uses thereof in infectious diseases |
US10369204B2 (en) | 2008-10-02 | 2019-08-06 | Dako Denmark A/S | Molecular vaccines for infectious disease |
WO2020033927A2 (en) | 2018-08-09 | 2020-02-13 | Juno Therapeutics, Inc. | Processes for generating engineered cells and compositions thereof |
WO2020048876A1 (en) | 2018-09-03 | 2020-03-12 | Technische Universitaet Muenchen | A double peptide tag combining reversibility and flexible functionalization |
US10611818B2 (en) | 2007-09-27 | 2020-04-07 | Agilent Technologies, Inc. | MHC multimers in tuberculosis diagnostics, vaccine and therapeutics |
WO2020089343A1 (en) | 2018-10-31 | 2020-05-07 | Juno Therapeutics Gmbh | Methods for selection and stimulation of cells and apparatus for same |
WO2020097132A1 (en) | 2018-11-06 | 2020-05-14 | Juno Therapeutics, Inc. | Process for producing genetically engineered t cells |
US10722562B2 (en) | 2008-07-23 | 2020-07-28 | Immudex Aps | Combinatorial analysis and repair |
WO2021041994A2 (en) | 2019-08-30 | 2021-03-04 | Juno Therapeutics, Inc. | Machine learning methods for classifying cells |
US10968269B1 (en) | 2008-02-28 | 2021-04-06 | Agilent Technologies, Inc. | MHC multimers in borrelia diagnostics and disease |
WO2021084050A1 (en) | 2019-10-30 | 2021-05-06 | Juno Therapeutics Gmbh | Cell selection and/or stimulation devices and methods of use |
WO2021122185A1 (en) | 2019-12-20 | 2021-06-24 | Miltenyi Biotec B.V. & Co. KG | Reversible cell detection via mhc with conjugates having an enzymatically cleavable detection moiety |
WO2021152178A1 (en) | 2020-01-31 | 2021-08-05 | Cell.Copedia GmbH | Methods of isolating a biological entity |
WO2021231661A2 (en) | 2020-05-13 | 2021-11-18 | Juno Therapeutics, Inc. | Process for producing donor-batched cells expressing a recombinant receptor |
WO2022234009A2 (en) | 2021-05-06 | 2022-11-10 | Juno Therapeutics Gmbh | Methods for stimulating and transducing t cells |
WO2023017115A1 (en) | 2021-08-11 | 2023-02-16 | Iba Lifesciences Gmbh | Fractionation of cells based on a marker protein |
EP4227423A1 (en) | 2022-02-09 | 2023-08-16 | Technische Universität München | Means and methods for identifying high affinity t-cells |
US11992518B2 (en) | 2008-10-02 | 2024-05-28 | Agilent Technologies, Inc. | Molecular vaccines for infectious disease |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040067532A1 (en) | 2002-08-12 | 2004-04-08 | Genetastix Corporation | High throughput generation and affinity maturation of humanized antibody |
EP1982176A1 (en) * | 2006-01-30 | 2008-10-22 | Dako Denmark A/S | High-speed quantification of antigen specific t-cells in whole blood by flow cytometry |
US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
CA2697193C (en) | 2007-09-14 | 2017-06-06 | Adimab, Inc. | Rationally designed, synthetic antibody libraries and uses therefor |
GB0817244D0 (en) | 2008-09-20 | 2008-10-29 | Univ Cardiff | Use of a protein kinase inhibitor to detect immune cells, such as T cells |
CN102575244B (en) * | 2009-09-17 | 2015-07-22 | Jsr株式会社 | Dissociation method and dissociation agent for avidin and biotin |
DK2567226T3 (en) | 2010-05-06 | 2016-10-10 | Adaptive Biotechnologies Corp | Monitoring the health and disease status using klonotypeprofiler |
AU2011305817B2 (en) * | 2010-09-21 | 2014-12-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-SSX-2 T cell receptors and related materials and methods of use |
WO2012044999A2 (en) * | 2010-10-01 | 2012-04-05 | Ludwig Institute For Cancer Research Ltd. | Reversible protein multimers, methods for their production and use |
WO2013056090A1 (en) * | 2011-10-12 | 2013-04-18 | University Of Connecticut | Affinity-based materials for the non-destructive separation and recovery of cells |
US10065996B2 (en) | 2012-11-16 | 2018-09-04 | Iba Gmbh | Streptavidin muteins and methods of using them |
WO2015095895A1 (en) | 2013-12-20 | 2015-06-25 | Fred Hutchinson Cancer Research Center | Tagged chimeric effector molecules and receptors thereof |
CN106414725B (en) | 2014-01-21 | 2020-12-18 | 干细胞技术公司 | Method for separating target entities from a sample using a surface-coupled monospecific tetrameric antibody complex composition |
AU2015249554B2 (en) | 2014-04-23 | 2021-08-19 | Juno Therapeutics, Inc. | Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy |
US11827904B2 (en) | 2015-04-29 | 2023-11-28 | Fred Hutchinson Cancer Center | Modified stem cells and uses thereof |
CA3020542A1 (en) | 2016-04-11 | 2017-10-19 | Board Of Regents, The University Of Texas System | Methods and compositions for detecting single t cell receptor affinity and sequence |
WO2018029350A2 (en) | 2016-08-11 | 2018-02-15 | Kite Pharma Eu B.V. | Methods of making and using soluble mhc molecules |
US10294454B2 (en) | 2016-08-24 | 2019-05-21 | General Electric Company | Methods and kits for cell activation |
EP3336545A1 (en) | 2016-12-13 | 2018-06-20 | Miltenyi Biotec GmbH | Reversible labeling of antigens in biological specimens |
EP3336546B1 (en) | 2016-12-13 | 2020-07-01 | Miltenyi Biotec B.V. & Co. KG | Reversible cell labelling with conjugates having two releasable binding sites |
WO2018134691A2 (en) | 2017-01-20 | 2018-07-26 | Juno Therapeutics Gmbh | Cell surface conjugates and related cell compositions and methods |
WO2019027850A1 (en) | 2017-07-29 | 2019-02-07 | Juno Therapeutics, Inc. | Reagents for expanding cells expressing recombinant receptors |
EP3489684B1 (en) | 2017-11-27 | 2024-06-26 | Miltenyi Biotec B.V. & Co. KG | Method for photobleaching stained cells |
KR20200108278A (en) | 2017-12-08 | 2020-09-17 | 주노 쎄러퓨티크스 인코퍼레이티드 | Method for preparing a composition of engineered T cells |
CN116148467A (en) * | 2017-12-12 | 2023-05-23 | 清华大学 | Complete reagent for detecting interaction between post-translational modification protein and ligand thereof |
EA202190693A1 (en) | 2018-09-11 | 2021-07-27 | Джуно Терапьютикс, Инк. | METHODS FOR ANALYSIS OF MASS SPECTROMETRY OF MODIFIED CELL COMPOSITIONS |
IL287049B1 (en) | 2019-04-09 | 2024-09-01 | Nurix Therapeutics Inc | 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus |
EP3953489A1 (en) | 2019-04-12 | 2022-02-16 | Miltenyi Biotec B.V. & Co. KG | Conjugates having an enzymatically releasable detection moiety and a barcode moiety |
JP2022532247A (en) | 2019-05-17 | 2022-07-13 | ニューリックス セラピューティクス,インコーポレイテッド | Cyanocyclobutyl compounds for Cbl-b inhibition and their use |
US20220220504A1 (en) | 2019-05-28 | 2022-07-14 | Miltenyi Biotec B.V. & Co. KG | Method for Generation of Genetically Modified T Cells |
CN114207136A (en) | 2019-06-07 | 2022-03-18 | 朱诺治疗学股份有限公司 | Automated T cell culture |
BR112021026241A2 (en) | 2019-06-26 | 2022-06-07 | Nurix Therapeutics Inc | Substituted benzyl triazole compounds for cbl-b inhibition and other uses thereof |
AU2020320195A1 (en) | 2019-07-30 | 2022-03-10 | Nurix Therapeutics, Inc. | Urea, amide, and substituted heteroaryl compounds for Cbl-b inhibition |
US20220315894A1 (en) | 2019-09-11 | 2022-10-06 | Miltenyi Biotec B.V. & Co. KG | Method for Transduction of T Cells in the Presence of Malignant Cells |
JP2023512209A (en) | 2020-01-28 | 2023-03-24 | ジュノー セラピューティクス インコーポレイテッド | Methods for T cell transduction |
US20230190798A1 (en) | 2020-02-12 | 2023-06-22 | Juno Therapeutics, Inc. | Cd19-directed chimeric antigen receptor t cell compositions and methods and uses thereof |
KR20220152227A (en) | 2020-02-12 | 2022-11-15 | 주노 쎄러퓨티크스 인코퍼레이티드 | BCA-directed chimeric antigen receptor T cell composition and methods and uses thereof |
EP3916393B1 (en) | 2020-05-27 | 2023-01-25 | Miltenyi Biotec B.V. & Co. KG | Method for detection of cells by repetitive staining and destaining |
WO2022043023A1 (en) | 2020-08-27 | 2022-03-03 | Miltenyi Biotec B.V. & Co. KG | Releasable reagents for cell separation |
EP4211471A1 (en) | 2020-09-07 | 2023-07-19 | Miltenyi Biotec B.V. & Co. KG | Conjugates having an enzymatically releasable detection moiety and a barcode moiety |
WO2023213969A1 (en) | 2022-05-05 | 2023-11-09 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
WO2023230581A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Methods of manufacturing t cell therapies |
WO2024100604A1 (en) | 2022-11-09 | 2024-05-16 | Juno Therapeutics Gmbh | Methods for manufacturing engineered immune cells |
WO2024124132A1 (en) | 2022-12-09 | 2024-06-13 | Juno Therapeutics, Inc. | Machine learning methods for predicting cell phenotype using holographic imaging |
WO2024161021A1 (en) | 2023-02-03 | 2024-08-08 | Juno Therapeutics Gmbh | Methods for non-viral manufacturing of engineered immune cells |
US20240285762A1 (en) | 2023-02-28 | 2024-08-29 | Juno Therapeutics, Inc. | Cell therapy for treating systemic autoimmune diseases |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996005287A1 (en) * | 1994-08-09 | 1996-02-22 | Anergen, Inc. | A method for the isolation of t cells from peripheral blood |
WO1997011183A1 (en) * | 1995-04-11 | 1997-03-27 | Trustees Of Boston University | Streptavidin mutants |
EP0835934A2 (en) * | 1996-10-10 | 1998-04-15 | Institut für Bioanalytik GmbH | Muteins of streptavidin |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4948590A (en) * | 1987-06-09 | 1990-08-14 | Yale University | Avidin or streptavidin conjugated liposomes |
DE4237113B4 (en) * | 1992-11-03 | 2006-10-12 | "Iba Gmbh" | Peptides and their fusion proteins, expression vector and method of producing a fusion protein |
AU716154B2 (en) * | 1995-09-01 | 2000-02-17 | University Of Washington | Interactive molecular conjugates |
US5985658A (en) * | 1997-11-14 | 1999-11-16 | Health Research Incorporated | Calmodulin-based cell separation technique |
FR2841905B1 (en) * | 2002-07-05 | 2004-09-03 | Centre Nat Rech Scient | FAB MUTANTS OF CHIMERE 13B8.2 ANTI-CD4 ANTIBODIES AND THEIR APPLICATIONS |
-
2000
- 2000-12-28 EP EP00128634A patent/EP1227321A1/en not_active Withdrawn
-
2001
- 2001-12-28 JP JP2002554713A patent/JP4416400B2/en not_active Expired - Lifetime
- 2001-12-28 CA CA2467434A patent/CA2467434C/en not_active Expired - Lifetime
- 2001-12-28 EP EP01986941.1A patent/EP1346217B1/en not_active Expired - Lifetime
- 2001-12-28 US US10/451,865 patent/US7776562B2/en not_active Expired - Lifetime
- 2001-12-28 WO PCT/EP2001/015353 patent/WO2002054065A2/en active Application Filing
-
2010
- 2010-07-26 US US12/843,763 patent/US8298782B2/en not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996005287A1 (en) * | 1994-08-09 | 1996-02-22 | Anergen, Inc. | A method for the isolation of t cells from peripheral blood |
WO1997011183A1 (en) * | 1995-04-11 | 1997-03-27 | Trustees Of Boston University | Streptavidin mutants |
EP0835934A2 (en) * | 1996-10-10 | 1998-04-15 | Institut für Bioanalytik GmbH | Muteins of streptavidin |
Non-Patent Citations (4)
Title |
---|
See also references of EP1346217A2 * |
VOSS SELMA ET AL: "Mutagenesis of a flexible loop in streptavidin leads to higher affinity for the Strep-tag II peptide and improved performance in recombinant protein purification." PROTEIN ENGINEERING, vol. 10, no. 8, August 1997 (1997-08), pages 975-982, XP002107709 ISSN: 0269-2139 * |
YEE C ET AL: "isolation of high avidity melanoma reactive CTL from heterogeneous populations using peptide-MHC tetramers" JOURNAL OF IMMUNOLOGY, 15 February 1999 (1999-02-15), XP002156019 * |
YOUDE SARAH J ET AL: "Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens." CANCER RESEARCH, vol. 60, no. 2, 15 January 2000 (2000-01-15), pages 365-371, XP002167445 ISSN: 0008-5472 * |
Cited By (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9133264B2 (en) | 2006-07-13 | 2015-09-15 | Max-Delbruck-Centrum Fur Molekulare Medizin (Mdc) Berlin-Buch | Epitope-tag surface expressed proteins and nucleic acids thereof |
WO2008006458A2 (en) * | 2006-07-13 | 2008-01-17 | Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) Berlin-Buch | Epitope-tag for surface-expressed t-cell receptor proteins, uses thereof and method of selecting host cells expressing them |
WO2008006458A3 (en) * | 2006-07-13 | 2008-03-06 | Max Delbrueck Centrum | Epitope-tag for surface-expressed t-cell receptor proteins, uses thereof and method of selecting host cells expressing them |
EP1878744A1 (en) * | 2006-07-13 | 2008-01-16 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Epitope-tag for surface-expressed T-cell receptor proteins, uses thereof and method of selecting host cells expressing them |
EP2518193A3 (en) * | 2006-11-15 | 2013-01-23 | Invitrogen Dynal AS | Methods for reversibly binding a biotin compound to a support |
EP2109669B1 (en) * | 2006-11-15 | 2015-01-07 | Life Technologies AS | Methods for reversibly binding a biotin compound to a support |
EP2518193A2 (en) * | 2006-11-15 | 2012-10-31 | Invitrogen Dynal AS | Methods for reversibly binding a biotin compound to a support |
EP2109669A2 (en) | 2006-11-15 | 2009-10-21 | Invitrogen Dynal AS | Methods for reversibly binding a biotin compound to a support |
US10336808B2 (en) | 2007-03-26 | 2019-07-02 | Dako Denmark A/S | MHC peptide complexes and uses thereof in infectious diseases |
US10030065B2 (en) | 2007-07-03 | 2018-07-24 | Dako Denmark A/S | MHC multimers, methods for their generation, labeling and use |
US10611818B2 (en) | 2007-09-27 | 2020-04-07 | Agilent Technologies, Inc. | MHC multimers in tuberculosis diagnostics, vaccine and therapeutics |
US10968269B1 (en) | 2008-02-28 | 2021-04-06 | Agilent Technologies, Inc. | MHC multimers in borrelia diagnostics and disease |
US10722562B2 (en) | 2008-07-23 | 2020-07-28 | Immudex Aps | Combinatorial analysis and repair |
US10369204B2 (en) | 2008-10-02 | 2019-08-06 | Dako Denmark A/S | Molecular vaccines for infectious disease |
US11992518B2 (en) | 2008-10-02 | 2024-05-28 | Agilent Technologies, Inc. | Molecular vaccines for infectious disease |
WO2013011011A3 (en) * | 2011-07-18 | 2013-05-02 | Iba Gmbh | Method of reversibly staining a target cell |
US9188589B2 (en) | 2011-07-18 | 2015-11-17 | Iba Gmbh | Method of reversibly staining a target cell |
US9023604B2 (en) | 2011-07-18 | 2015-05-05 | Iba Gmbh | Method of reversibly staining a target cell |
WO2013011011A2 (en) | 2011-07-18 | 2013-01-24 | Iba Gmbh | Method of reversibly staining a target cell |
EP3418295A1 (en) | 2011-07-18 | 2018-12-26 | IBA GmbH | Method of reversibly staining a target cell |
WO2013124474A2 (en) | 2012-02-23 | 2013-08-29 | Stage Cell Therapeutics Gmbh | Chromatographic isolation of cells and other complex biological materials |
RU2746407C1 (en) * | 2012-02-23 | 2021-04-13 | Стейдж Селл Терапеутикс Гмбх | Chromatographic isolation of cells and other complex biological materials |
US12066365B2 (en) | 2012-02-23 | 2024-08-20 | Juno Therapeutics Gmbh | Chromatographic isolation of cells and other complex biological materials |
US10228312B2 (en) | 2012-02-23 | 2019-03-12 | Juno Therapeutics Gmbh | Chromatographic isolation of cells and other complex biological materials |
CN102662054A (en) * | 2012-05-10 | 2012-09-12 | 东南大学 | Method for synchronously detecting quantity and functions of specific thymus dependent lymph cells |
WO2015158868A3 (en) * | 2014-04-16 | 2016-01-28 | Juno Therapeutics Gmbh | Methods, kits and apparatus for expanding a population of cells |
WO2015158868A2 (en) | 2014-04-16 | 2015-10-22 | Juno Therapeutics Gmbh | Methods, kits and apparatus for expanding a population of cells |
US11274278B2 (en) | 2014-04-16 | 2022-03-15 | Juno Therapeutics Gmbh | Methods, kits and apparatus for expanding a population of cells |
EP3988920A1 (en) | 2014-04-16 | 2022-04-27 | Juno Therapeutics GmbH | Methods, kits and apparatus for expanding a population of cells |
US11150239B2 (en) | 2014-04-30 | 2021-10-19 | Iba Lifesciences Gmbh | Method of isolating a target cell |
WO2015166049A1 (en) | 2014-04-30 | 2015-11-05 | Iba Gmbh | Method of isolating a target cell |
EP3037821A1 (en) * | 2014-12-27 | 2016-06-29 | Miltenyi Biotec GmbH | Cell detection with conjugates having an enzymatically releasable detection moiety |
US10197561B2 (en) | 2014-12-27 | 2019-02-05 | Miltenyi Biotec, Gmbh | Cell detection with conjugates having an enzymatically releasable detection moiety |
WO2016166568A1 (en) | 2015-04-16 | 2016-10-20 | Juno Therapeutics Gmbh | Methods, kits and apparatus for expanding a population of cells |
WO2017056362A1 (en) * | 2015-09-30 | 2017-04-06 | Sony Corporation | Method for analyzing cell, chip for cell analysis, reagent for cell analysis, kit for cell analysis, and apparatus for cell analysis |
US11199541B2 (en) | 2015-09-30 | 2021-12-14 | Sony Corporation | Method for analyzing cell, chip for cell analysis, reagent for cell analysis, kit for cell analysis, and apparatus for cell analysis |
US11248238B2 (en) | 2015-10-22 | 2022-02-15 | Juno Therapeutics Gmbh | Methods, kits, agents and apparatuses for transduction |
RU2761557C2 (en) * | 2015-10-22 | 2021-12-09 | Джуно Терапьютикс Гмбх | Methods for cell cultivation and sets and device for them |
WO2017068421A1 (en) | 2015-10-22 | 2017-04-27 | Juno Therapeutics Gmbh | Methods for culturing cells and kits and apparatus for same |
CN108431210A (en) * | 2015-10-22 | 2018-08-21 | 朱诺治疗学有限公司 | Cultivate the method for cell and kit and equipment for this method |
WO2017068419A2 (en) | 2015-10-22 | 2017-04-27 | Juno Therapeutics Gmbh | Methods, kits, agents and apparatuses for transduction |
US11913024B2 (en) | 2015-10-22 | 2024-02-27 | Juno Therapeutics Gmbh | Methods for culturing cells and kits and apparatus for same |
WO2017068425A1 (en) | 2015-10-22 | 2017-04-27 | Juno Therapeutics Gmbh | Methods for culturing cells and kits and apparatus for same |
US11466253B2 (en) | 2015-10-22 | 2022-10-11 | Juno Therapeutics Gmbh | Methods for culturing cells and kits and apparatus for same |
US11320431B2 (en) | 2016-06-28 | 2022-05-03 | Technische Universitaet Muenchen | Combination of reversible and irreversible cell labeling for analizing receptor-ligand koff rate |
WO2018001985A1 (en) | 2016-06-28 | 2018-01-04 | Technische Universitaet Muenchen | Combination of reversible and irreversible cell labeling for analizing receptor-ligand koff rate |
US11866465B2 (en) | 2017-04-27 | 2024-01-09 | Juno Therapeutics Gmbh | Oligomeric particle reagents and methods of use thereof |
WO2018197949A1 (en) | 2017-04-27 | 2018-11-01 | Juno Therapeutics Gmbh | Oligomeric particle reagents and methods of use thereof |
WO2020033927A2 (en) | 2018-08-09 | 2020-02-13 | Juno Therapeutics, Inc. | Processes for generating engineered cells and compositions thereof |
WO2020048876A1 (en) | 2018-09-03 | 2020-03-12 | Technische Universitaet Muenchen | A double peptide tag combining reversibility and flexible functionalization |
WO2020089343A1 (en) | 2018-10-31 | 2020-05-07 | Juno Therapeutics Gmbh | Methods for selection and stimulation of cells and apparatus for same |
WO2020097132A1 (en) | 2018-11-06 | 2020-05-14 | Juno Therapeutics, Inc. | Process for producing genetically engineered t cells |
WO2021041994A2 (en) | 2019-08-30 | 2021-03-04 | Juno Therapeutics, Inc. | Machine learning methods for classifying cells |
WO2021084050A1 (en) | 2019-10-30 | 2021-05-06 | Juno Therapeutics Gmbh | Cell selection and/or stimulation devices and methods of use |
WO2021122185A1 (en) | 2019-12-20 | 2021-06-24 | Miltenyi Biotec B.V. & Co. KG | Reversible cell detection via mhc with conjugates having an enzymatically cleavable detection moiety |
WO2021152178A1 (en) | 2020-01-31 | 2021-08-05 | Cell.Copedia GmbH | Methods of isolating a biological entity |
EP4180811A1 (en) | 2020-01-31 | 2023-05-17 | Cell.copedia GmbH | Methods of isolating a biological entity |
WO2021231661A2 (en) | 2020-05-13 | 2021-11-18 | Juno Therapeutics, Inc. | Process for producing donor-batched cells expressing a recombinant receptor |
WO2022234009A2 (en) | 2021-05-06 | 2022-11-10 | Juno Therapeutics Gmbh | Methods for stimulating and transducing t cells |
WO2023017115A1 (en) | 2021-08-11 | 2023-02-16 | Iba Lifesciences Gmbh | Fractionation of cells based on a marker protein |
EP4227423A1 (en) | 2022-02-09 | 2023-08-16 | Technische Universität München | Means and methods for identifying high affinity t-cells |
WO2023152221A1 (en) | 2022-02-09 | 2023-08-17 | Technische Universität München | Means and methods for identifying high affinity t-cells |
Also Published As
Publication number | Publication date |
---|---|
US20040082012A1 (en) | 2004-04-29 |
US20110070605A1 (en) | 2011-03-24 |
JP4416400B2 (en) | 2010-02-17 |
US8298782B2 (en) | 2012-10-30 |
EP1346217B1 (en) | 2020-10-21 |
WO2002054065A3 (en) | 2002-11-28 |
EP1227321A1 (en) | 2002-07-31 |
CA2467434A1 (en) | 2002-07-11 |
JP2004525354A (en) | 2004-08-19 |
CA2467434C (en) | 2013-02-19 |
US7776562B2 (en) | 2010-08-17 |
EP1346217A2 (en) | 2003-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1346217B1 (en) | Reversible mhc multimer staining for functional purification of antigen-specific t cells | |
JP6770989B2 (en) | How to reversibly stain target cells | |
US11913024B2 (en) | Methods for culturing cells and kits and apparatus for same | |
EP3132247B1 (en) | Methods, kits and apparatus for expanding a population of cells | |
AU2002240818B2 (en) | MHC molecule constructs and their uses for diagnosis and therapy | |
JP4976294B2 (en) | Cytotoxic T cell epitope peptide and use thereof | |
US20150329617A1 (en) | Novel MHC molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of MHC molecules | |
WO2010037397A1 (en) | Mhc multimers in cmv immune monitoring | |
WO2016166568A1 (en) | Methods, kits and apparatus for expanding a population of cells | |
JP5020452B2 (en) | Means for the detection and purification of CD8 + T lymphocyte populations specific for peptides presented in the context of HLA | |
WO2002044205A2 (en) | Peptides from ag85 of mycobacterium and uses thereof | |
Risnes | Generation of MHC II Streptamers for gluten-specific CD4+ T cells | |
JP2017132745A (en) | Hla-a24 restrictive ctl epitope peptide derived from hhv-6b-specific antigen u54 and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001986941 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002554713 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001986941 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10451865 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2467434 Country of ref document: CA |